Northstar brain therapy fails late-stage trial

Northstar Neuroscience says that a brain stimulation therapy intended to improve hand and arm function in stroke victims flunked a late-stage trial. Northstar's treatment uses electrical stimulation to the brain, but it failed to improve limb function by 20 percent, the primary goal of the trial. Seattle-based Northstar says it is unlikely that the data warrants FDA approval for that, but adds that it still has potential for other conditions, including depression and tinnitus.

- see this release
- check out the AFX report

Suggested Articles

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.

After its mega $424 million IPO this summer, blood cancer focused Legend Biotech is making a big change at the top.